Vascular Solutions' Duett Reduces Time To Hemostasis - Final SEAL Data
This article was originally published in The Gray Sheet
Executive Summary
Time to hemostasis during interventional procedures was "significantly and noticeably decreased" using Vascular Solutions' Duett femoral closure device compared to manual compression, Stephen Ellis, MD, Cleveland Clinic, told attendees of the American Heart Association's scientific sessions Nov. 9 in Atlanta.
You may also be interested in...
Vascular Solutions Preparing For Duett Vascular Sealing Launch, Going Public
Vascular Solutions says it will allocate roughly $12 mil. of its upcoming $40 mil. initial public offering to establish a direct U.S. sales force over the next year to market the Duett vascular sealing device, which currently awaits FDA approval.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.